India Liver Cancer Therapeutics Market Report 2022 to 2030

India Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the India liver cancer therapeutics market will reach a value of $238.4 Mn from $53.3 Mn in 2022, growing at a CAGR of 20.6% during 2022-30. The liver cancer therapeutics in India is dominated by a few domestic pharmaceutical companies such as Dr. Reddy's Laboratories, HCG Hospitals, and Natco Pharma. The liver cancer therapeutics market in India is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10INPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Dr. Vishwa Modhia

Buy Now

India Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the India liver cancer therapeutics market will reach a value of $238.4 Mn from $53.3 Mn in 2022, growing at a CAGR of 20.6% during 2022-2030.

India is a lower middle-income, developing country located in Southern Asia bordering the Arabian Sea and the Bay of Bengal. Liver or Hepatocellular cancers account for around 6% of all gastrointestinal cancers diagnosed in India as a result of alcohol addiction. According to the most recent WHO data, 30,369 people died from liver cancer in India in 2020, accounting for 0.36 % of all fatalities. With an age-adjusted death rate of 2.67 per 100,000 population, India ranks 175th in the world.

Liver cancer is a rising healthcare issue in India, with the number of cases increased significantly over the last several decades. The condition affects men more than women and is most typically diagnosed in adults aged 40 and up. In 2020, India's government spent 3% of its GDP on healthcare.

india liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

The Indian market for liver cancer therapies is predicted to increase significantly over the forecast period. One of the primary growth drivers is an increase in the incidence of liver cancer caused by risk factors such as hepatitis B and C, non-alcoholic fatty liver disease, and alcoholic liver disease. A growing geriatric population, changing lifestyles, and increased awareness about cancer screening and treatment choices are further driving growth in the Indian liver cancer treatment market.

Market Restraints

Many patients in India, particularly in rural regions, have limited access to healthcare services. This can make it difficult for them to receive prompt and efficient liver cancer treatment. Adherence to regulatory guidelines established by organizations such as India's Central Drugs Standard Control Organization is required while developing new medications and therapies (CDSCO). These factors may deter new entrants into the India Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

Natco Pharma: Natco Pharma is an Indian pharmaceutical company that develops and manufactures drugs for various diseases, including liver cancer
Dr. Reddy's Laboratories: Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that develops and manufactures drugs for various diseases, including liver cancer
Cadila Healthcare: Cadila Healthcare is an Indian multinational pharmaceutical company that develops and manufactures drugs for various diseases, including liver cancer
Hetero Drugs: Hetero Drugs is an Indian pharmaceutical company that develops and manufactures drugs for various diseases, including liver cancer
HCG Hospitals: HCG Hospitals is a chain of hospitals in India that provides comprehensive cancer care, including liver cancer treatment
Apollo Hospitals: Apollo Hospitals is a chain of hospitals in India that provides comprehensive cancer care, including liver cancer treatment

Recent Notable Updates

February 2023: Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., announced the signing of a formal deal to purchase Mayne Pharma Group Limited's U.S. generic prescription product portfolio. The acquisition will provide limited competition products to Dr. Reddy's retail prescription pharmaceutical business in the United States. It also helps Dr. Reddy's efforts to speed and increase patient access to cheap pharmaceuticals.

Healthcare Policies and Reimbursement Scenarios

In India, the regulatory body responsible for approving liver cancer therapeutics is the Central Drugs Standard Control Organization (CDSCO), which is under the Ministry of Health and Family Welfare. The reimbursement of liver cancer therapeutics in India is largely determined by the national health insurance system, which is managed by the Ministry of Health and Family Welfare.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

India Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.